Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 7/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.65 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.65 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 6/20 | 0.35 |
| ▸ | RAB9A | P51151 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talarozole SCHEMBL4984008 | 0.79 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| Talarozole SCHEMBL3739251 | 0.79 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| Talarozole SCHEMBL721201 | 0.79 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| Talarozole SCHEMBL21020998 | 0.79 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL24259982 | 0.77 | CYP26A1 (0.72) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL4048034 | 0.71 | CYP26A1 (0.49) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL11676698 | 0.69 | RAB9A (0.61) | PDE10ANPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4054105 | 0.69 | CYP26A1 (0.52) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL4986440 | 0.68 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL9005425 | 0.67 | CYP26A1 (0.77) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378433-B2 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-27 | — | — | US | disclosed |
| US-20070088062-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. | 2007-04-19 | — | — | US | disclosed |
| US-7205312-B2 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-20050113378-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. | 2005-05-26 | — | — | US | disclosed |
| US-6833375-B2 | As inhibitors of the retinoic acid-metabolism, as drugs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-21 | — | — | US | disclosed |
| US-20030176419-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | VENET MARC GASTON (FR) | 2003-09-18 | — | — | US | disclosed |
| EP-0907650-B1 | N- 4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES | JANSSEN PHARMACEUTICA NV (BE) | 2002-12-04 | — | — | EP | disclosed |
| US-6486187-B1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-11-26 | — | — | US | disclosed |
| US-6124330-A | A RETINOIC MIMETIC COMPOUND FOR TREATING A WARM-BLOODED ANIMAL SUFFERING FROM A DISEASE BY AN ABNORMAL PROLIFERATION AND/OR ABNORMAL DIFFERENTIATION OF NORMAL, PRENEOPLASTIC OR NEOPLASTIC CELLS | JANSSEN-CILAG S.A. (FR) | 2000-09-26 | — | — | US | disclosed |
| EP-0907650-A1 | N- 4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049704-A1 | N-[4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113378-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | CYP2S1, CYP2D6, CYP2C19 | CYP26A1 61/4885CYP3A4 5/4885CYP2C9 4/4885 |
| US-20030176419-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | CYP8B1, CYP2S1, CYP2B6 | CYP26A1 40/4885CYP3A4 15/4885CYP2C9 16/4885 |
| US-20070088062-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | CYP2S1, CYP2D6, CYP2C19 | CYP26A1 61/4885CYP3A4 5/4885CYP2C9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.